Effect of Semaglutide in Patients With Psoriasis and Obesity

NCT06937060 on ClinicalTrials.gov · last registry update 2025-05-13

A small phase 3 — 14 participants, against a typical 424. Its estimated completion date, 31 July 2026, has passed with no update to the record. Primary outcome, as filed: Change in mean Psoriasis Area and Severity Index (PASI) before and after semaglutide treatment. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: RECRUITING
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: The University of Hong Kong
Sponsor type: Other
Enrollment: 14
Started: 2025-03-20
Primary completion: 2026-07-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in mean Psoriasis Area and Severity Index (PASI) before and after semaglutide treatment.

Conditions studied

Psoriasis (PsO) · Obesity and Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.